Abstract 84P
Background
Several studies showed that sex is a biological variable that influence immune response in several types of solid tumors; however, there is scarce information in hematological malignancies. In this work, we evaluate differences in immune cells compositions and immune response of multiple myeloma between sexes.
Methods
We conducted a computational biology study using transcriptomic data obtained from bone marrow aspiration collected from untreated multiple myeloma patients under the MMRF-COMMPASS protocol (study accession phs000748). Data was pre-processed and the expression levels were normalized to TPM (transcript per million). To evaluate differences in immune cells compositions, we quantified the immune cell in the tumor microenvironment with the analytic platform CIBERSORT. Differences in activated immune pathways was evaluated with the gene set enrichment analysis (GSEA). Pre-processed counts were normalized to TMM (trimmed mean of M-values) and GSEA was performed using the GSEA java desktop application (v4.3.2). In both analysis, patterns of immune gene sets and the immune cell composition were compared between tumors from female vs. male patients. A p<0.05 and a FDR<25% were considered statistically significant for GSEA analysis, while a p<0.05 and a FDR<0.05 6.1x10-5 was considered statistically significant for CIBERSORT analysis.
Results
Overall, 451 males and 313 female patients were included. We detected in samples from female patients an enrichment of dendritic cells activated (p=0.0023, FDR=0,0257) and NK cells activated (p=0.0059, FDR=0,0326). In contrast, we observed in male patients an enrichment of monocytes (p=6.10x 10 -5 , FDR=0,0013) and macrophages M1(p=0,0050, FDR=0,0326). The GSEA analysis revealed an overregulation of natural killer cell degranulation (p=0.007, FDR=0.21624), positive regulation of type I interferon mediated signaling pathway (p<0.0001, FDR=0.23946), and regulation of natural killer cell proliferation (p=0.01, FDR=0.2495).
Conclusions
The computational analysis showed some differences in the immune microenvironment, between sexes in multiple myeloma. Studies about the influence of these differences in the clinical outcomes of patients should be evaluated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
514P - Immunophenotypic profile of glioblastoma microenvironment: A cohort study
Presenter: Lidia Gatto
Session: Poster session 09
515P - A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
Presenter: Shu Zhou
Session: Poster session 09
516P - Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
Presenter: Kristi Beshiri
Session: Poster session 09
517P - Differentiating IDH-wildtype and IDH-mutant high grade gliomas with deep learning
Presenter: Katherine Hewitt
Session: Poster session 09